Drug Recall: PEPTIME Energy Tablets cGMP Deviations
Ultra Seal Corporation is voluntarily recalling PEPTIME Energy (caffeine 250mg) tablets distributed nationwide due to manufacturing practice deviations. The recall affects 156,096 packets and 9,648 bottles.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for manufacturing practice deviations (cGMP). The source text does not report any illnesses, injuries, or hospitalizations, and the hazard is procedural rather than inherent to the product itself. Class II recalls without reported illness or injury typically warrant a Moderate severity score.
Plain-English summary
Ultra Seal Corporation is voluntarily recalling PEPTIME Energy caffeine 250mg tablets distributed nationwide within the United States. The product is packaged in two formats: 6-count packets (Lot #19E021, approximately 156,096 packets) and 100-count bottles (Lot #19E022, approximately 9,648 bottles). The product is marketed by DMD Pharmaceuticals, A Division of Dickery Consumer Products, Inc., Noblesville, IN 46060.
The recall was initiated because of cGMP (current good manufacturing practice) deviations identified during manufacturing. The recall was initiated on January 24, 2022, classified as FDA Class II on January 31, 2022, and voluntarily undertaken by the manufacturing firm. The recall was terminated on October 16, 2023.
Consumers who have purchased affected lots should contact the manufacturer or their retailer for further instructions.
The recalled product
- Product
- PEPTIME Energy (caffeine 250mg) tablets, packaged in a) 6 count packets and b) 100-count bottles, Marketed by: DMD Pharmaceuticals, A Division of Dickery Consumer Products, Inc., Noblesville, IN 46060.
- Manufacturer
- Ultra Seal Corporation
- Category
- Drug — Caffeine supplement
- Hazard
- cgmp-deviation
- manufacturing-practice
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: a)19E021
- b)19E022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27